{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:03:53Z","timestamp":1769760233940,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10067-023-06862-8","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T03:02:08Z","timestamp":1704510128000},"page":"1447-1459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0149-9434","authenticated-orcid":false,"given":"Hiroshi","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Maeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Shono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Tsuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"issue":"1","key":"6862_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-020-02194-z","volume":"22","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR (2020) Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther 22(1):139. https:\/\/doi.org\/10.1186\/s13075-020-02194-z","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"6862_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10067-014-2750-8","volume":"34","author":"A Nakajima","year":"2015","unstructured":"Nakajima A, Inoue E, Shimizu Y, Kobayashi A, Shidara K, Sugimoto N, Seto Y, Tanaka E, Taniguchi A, Momohara S, Yamanaka H (2015) Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clin Rheumatol 34(3):441\u2013449. https:\/\/doi.org\/10.1007\/s10067-014-2750-8","journal-title":"Clin Rheumatol"},{"issue":"1","key":"6862_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","volume":"72","author":"M Dougados","year":"2013","unstructured":"Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TWJ (2013) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 72(1):43\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201282","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6862_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, Bernasconi C, Huizinga TWJ (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73(5):803\u2013809. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204761","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6862_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/rheumatology\/kex443","volume":"57","author":"E Choy","year":"2018","unstructured":"Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Peth\u00f6-Schramm A (2018) Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford) 57(3):499\u2013507. https:\/\/doi.org\/10.1093\/rheumatology\/kex443","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"6862_CR6","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TWJ Huizinga","year":"2014","unstructured":"Huizinga TWJ, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC (2014) Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 73(9):1626\u20131634. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204405","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6862_CR7","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/rheumatology\/keab676","volume":"61","author":"GR Burmester","year":"2022","unstructured":"Burmester GR, Bykerk VP, Buch MH, Tanaka Y, Kameda H, Praestgaard A, van Hoogstraten H, Fernandez-Nebro A, Huizinga T (2022) Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) 61(6):2596\u20132602. https:\/\/doi.org\/10.1093\/rheumatology\/keab676","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"6862_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/14397595.2019.1639939","volume":"30","author":"H Kameda","year":"2020","unstructured":"Kameda H, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham N, Tanaka Y (2020) Sarilumab monotherapy or in combination with non-methotrexate disease modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). Mod Rheumatol 30(2):239\u2013248. https:\/\/doi.org\/10.1080\/14397595.2019.1639939","journal-title":"Mod Rheumatol"},{"issue":"1","key":"6862_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz A, Choy E, Dougados M, Jacobs JW, Geenen R, Bijlsma HW, Zink A, Aletaha D, Schoneveld L, van Riel P, Gutermann L, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 80(1):31\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"6862_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"6","key":"6862_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"issue":"3","key":"6862_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely-available easy-to-use software \u201cEZR\u201d (Easy R) for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6862_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","volume":"66","author":"A Ogata","year":"2014","unstructured":"Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, Ohta S, Saeki Y, Tanaka T, Musashi Study Investigators (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 66(3):344\u2013354. https:\/\/doi.org\/10.1002\/acr.22110","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"6862_CR14","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/acr.22384","volume":"66","author":"A Kivitz","year":"2014","unstructured":"Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE (2014) Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 66(11):1653\u20131661. https:\/\/doi.org\/10.1002\/acr.22384","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"6862_CR15","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NMH, Stahl N, Yancopoulos GD, Huizinga TWJ, van der Heijde D (2015) Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol 67(6):1424\u20131437. https:\/\/doi.org\/10.1002\/art.39093","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"6862_CR16","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1093\/rheumatology\/keaa860","volume":"60","author":"NMT Roodenrijs","year":"2021","unstructured":"Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, Lafeber FPJG, Jacobs JWG, van Laar JM (2021) Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford) 60(8):3778\u20133788. https:\/\/doi.org\/10.1093\/rheumatology\/keaa860","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"6862_CR17","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal L, Lwin MN, Holroyd C, Edwards CJ (2020) Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun Rev 19(6):102528. https:\/\/doi.org\/10.1016\/j.autrev.2020.102528","journal-title":"Autoimmun Rev"},{"issue":"2","key":"6862_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","volume":"59","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, Gomez-Reino JJ, Maldonado-Cocco JA, Stanislav M, Kivitz AJ, Burmester GR (2020) Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years\u2019 follow-up. Rheumatology (Oxford) 59(2):292\u2013302. https:\/\/doi.org\/10.1093\/rheumatology\/kez265","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"6862_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13075-019-1856-4","volume":"21","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NMH, Kameda H (2019) Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther 21(1):79. https:\/\/doi.org\/10.1186\/s13075-019-1856-4","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"6862_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Delsberg AJ, Lin Y, Castelar-Pinheiro CR, Brzezicki J, Hrycaj P, Neil MH, Graham NMH, van Hoogstraten H, Bauer D, Burmester GR (2017) Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 69(2):277\u2013290. https:\/\/doi.org\/10.1002\/art.39944","journal-title":"Arthritis Rheumatol."},{"key":"6862_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rap\/rkac002","volume":"00","author":"HP Tony","year":"2022","unstructured":"Tony HP, Feist E, Aries PM, Zinke S, Kruger K, Ahlers J, Albrecht I, Barrionuevo C, Kalus S, Burkhardt H (2022) Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany. Rheumatology Advances in Practice 00:1\u20137. https:\/\/doi.org\/10.1093\/rap\/rkac002","journal-title":"Rheumatology Advances in Practice"}],"updated-by":[{"DOI":"10.1007\/s10067-024-06907-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06862-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06862-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06862-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T05:11:26Z","timestamp":1713157886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06862-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6862"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06862-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-024-06907-6","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]},"assertion":[{"value":"21 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-024-06907-6","URL":"https:\/\/doi.org\/10.1007\/s10067-024-06907-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuharu Nakashima has received lecture fees in excess of 3,500 USD from Daiichi Sankyo Co., Ltd. Hiroaki Niiro has received lecture fees in excess of 3,500 USD from Mitsubishi Tanabe Pharma Corporation, Asahi Kasei Pharma Corporation, Eisai Co., Ltd., GlaxoSmithKline K.K., Bristol Myers Squibb, Eli Lilly Japan K.K., and Chugai Pharmaceutical Co., Ltd.The other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}